FINWIRES · TerminalLIVE
FINWIRES

ASX:TTX

6 stories mentioning ASX:TTXUpdated 16d ago

Every FINWIRES story that references ASX:TTX, newest first.

Wire

Tetratherix Improves Cash Position With Inaugural Superpower License Fee, Capital Raise

Tetratherix (ASX:TTX) received its first license fee revenue of $3 million in the June quarter as part of an exclusive research and development agreement with US consumer health group Superpower, according to a Wednesday filing with the Australian bourse.The fee revenue, combined with a net AU$14.7 million from a placement in May, left the company with a "strong cash position" of AU$34.4 million as of June 30, per the filing.The company closed the March quarter with AU$19.2 million of cash on hand, a previous filing showed.Tetratherix said it saw AU$19.3 million of cash inflows in the three months through June, bringing the total to AU$21.9 million for the full 2026 fiscal year.

ASX:TTX
Asia

Tetratherix Joint Venture Gets Ethics Approval for Clinical Trial of Hydrogel Spacer in Cancer Treatments

Tetratherix (ASX:TTX) said its Tutelix joint venture received ethics committee approval to launch a clinical trial for hydrogel spacer in Australia, according to a Tuesday filing with the Australian bourse.The Tutelix hydrogel spacer is used during cancer treatments to protect healthy parts of the body from damage.Positive six-month follow-up data confirms an opportunity for the product beyond the prostate cancer program, providing the company with a technical basis to pursue a gynaecological cancer indication, Tetratherix Chief Technology Officer Ali Fathi said.The clinical study has completed enrolment of all 15 patients across multiple Australian sites, per the filing.

ASX:TTX
Asia

Tetratherix Completes Share Purchase Plan

Tetratherix (ASX:TTX) completed its share purchase plan, receiving applications totaling AU$639,644 at an issue price of AU$6 apiece, according to a Monday filing with the Australian bourse.Proceeds will be used to fund production expansion, strategic partnerships, customer success, digitalization, working capital, and offer costs, the filing said.

ASX:TTX
Asia

Tetratherix Says Research Validation of Polymer Product Confirms Enabling of Direct Absorption into the Bloodstream

Tetratherix (ASX:TTX) said further research validation of the Tetramatrix platform polymer product confirmed it forms a protective, adhesive carrier on the nasal lining, guarding compounds from degradation and enabling direct absorption into the bloodstream, according to a Tuesday Australian bourse filing.The peer-reviewed study applied the product to insulin, confirming greater than 99% encapsulation, stability, protection from enzymatic degradation, and statistically superior compound delivery to the bloodstream and brain compared with unformulated insulin.Another study tested the product against bovine serum albumin and showed high encapsulation efficiency, stability over four weeks when refrigerated, zero cytotoxicity, greater deposition in the olfactory region, and a statistically significant increase in the tightening of nasal cell junctions.The studies were led by researchers at the Woolcock Institute of Medical Research, a Tetratherix research collaborator.Its shares rose 1% in recent trading on Tuesday.

ASX:TTX
Asia

Tetratherix Raises AU$15 Million Via Institutional Placement; Shares Tumble 6%

Tetratherix (ASX:L) said it has received firm commitments from new and existing institutional investors to raise AU$15 million through a placement at AU$6 per share, representing a 2% discount to the 10-day volume-weighted average price of AU$6.12, according to a Thursday Australian bourse filing.The company said tranche 1 shares are anticipated to settle on June 3, while tranche 2 shares issued to directors are subject to shareholder approval at a general meeting.The company will also offer a share purchase plan (SPP) to existing eligible shareholders to raise a further AU$2 million, with proceeds from the placement and SPP to be used to fund production expansion, strategic partnerships, customer success, digitalization, working capital, and transaction costs.The company's shares tumbled 6% in recent Thursday trade.

ASX:TTX
Asia

Market Chatter: Tetratherix Seeks to Raise Around AU$15 Million Via Equity Raise, AFR Says

Tetratherix (ASX:TTX) is reportedly looking to raise around AU$15 million from an equity raising at AU$6 per share, and it has brought in Barrenjoey Capital Partners and Morgans, the Australian Financial Review (AFR) reported on Tuesday.The offering is said to be cornerstoned by a global healthcare investor, the report said.The firm requested a halt in trading of its shares from the open of trading on Tuesday in connection with a proposed material capital raising, according to a same-day Australian bourse filing.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

ASX:TTX

Track with the FINWIRES app suite

FolioX
FolioX
Track ASX:TTX in your portfolio
WheelAI
WheelAI
Analyze ASX:TTX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ASX:TTX